

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application. Please cancel claims 1-65 and replace with the following new claims.

Listing of Claims:

66. (New) A fusion polypeptide comprising a collagen-binding domain and an epithelial cell proliferation-modulating domain.
67. (New) The fusion polypeptide of claim 66, wherein the epithelial cell proliferation-modulating agent stimulates epithelial cell proliferation.
68. (New) The fusion polypeptide of Claim 66, wherein the collagen-binding domain is a collagen-binding domain of von Willebrand factor.
69. (New) The fusion polypeptide of claim 68, wherein the collagen-binding domain of von Willebrand factor comprises the decapeptide WREPSFMALS (SEQ ID NO:1).

70. (New) The fusion protein of Claim 66, wherein the epithelial cell proliferation-modulating domain is a growth factor.
71. (New) The fusion polypeptide of claim 70, wherein the growth factor is epidermal growth factor (EGF).
72. (New) A nucleic acid sequence encoding a fusion polypeptide comprising a collagen-binding domain and an epithelial cell proliferation-modulating domain.
73. (New) The nucleic acid sequence of claim 72, operably linked to a promoter.
74. (New) An expression vector comprising the nucleic acid sequence of claim 72.
75. (New) The expression vector of claim 74, wherein the expression vector is a retroviral vector.

76. (New) A host cell comprising the nucleic acid sequence of claim 72.
77. (New) A method of producing the fusion polypeptide comprising a collagen-binding domain and an epithelial cell proliferation-modulating domain, comprising growing the host cells of claim 76 under conditions that allow expression of the fusion polypeptide recovering the fusion polypeptide.
78. (New) The method of claim 77, wherein the host is a prokaryotic cell.
79. (New) The method of claim 77, wherein the host is a eukaryotic cell.
80. (New) A pharmaceutical composition comprising a fusion polypeptide comprising a collagen-binding domain and an epithelial cell proliferation-modulating domain, in a pharmaceutically acceptable carrier.